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Cardiovascular diseases such as atherosclerosis are one of the leading causes of morbidity
andmortality worldwide.The clinical manifestations of atherosclerosis, which include heart
attack and stroke, occur several decades after initiation of the disease and become more
severe with age. Inﬂammation of blood vessels plays a prominent role in atherogenesis.
Activation of the endothelium by inﬂammatory mediators leads to the recruitment of
circulating inﬂammatory cells, which drives atherosclerotic plaque formation and pro-
gression. Inﬂammatory signaling within the endothelium is driven predominantly by the
pro-inﬂammatory transcription factor, NF-κB. Interestingly, activation of NF-κB is enhanced
during the normal aging process and this may contribute to the development of cardio-
vascular disease. Importantly, studies utilizing mouse models of vascular inﬂammation
and atherosclerosis are uncovering a network of noncoding RNAs, particularly microRNAs,
which impinge on the NF-κB signaling pathway. Here we summarize the literature regarding
the control of vascular inﬂammation by microRNAs, and provide insight into how these
microRNA-based pathways might be harnessed for therapeutic treatment of disease. We
also discuss emerging areas of endothelial cell biology, including the involvement of long
noncoding RNAs and circulating microRNAs in the control of vascular inﬂammation.
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AGING, NF-κB ACTIVITY, AND INFLAMMATION
While classical risk factors for the development of cardiovascular
disease are well established (such as hyperlipidemia, hypertension,
smoking, obesity, physical inactivity, and diabetes), age is also a
major risk factor, and the incidence and severity of the clinical
manifestations of cardiovascular disease rise precipitously with
advanced age (Lakatta and Levy, 2003). This is due, in part, to
the acquisition of endothelial dysfunction in aging vessels, which
reduces vascular responsiveness and contributes to the develop-
ment of hypertension (Lakatta and Levy, 2003). A key mediator
of endothelial dysfunction is the pro-inﬂammatory transcription
factor nuclear factor of κ light polypeptide gene enhancer in B
cells (NF-κB; Csiszar et al., 2008). The NF-κB transcription fac-
tor is composed of homo- or hetero-dimers of RelA (p65), RelB,
c-Rel, p50/p105 (NF-κB1), or p52/p100 (NF-κB2; Hayden and
Ghosh, 2004), with p65/p50 heterodimers being the predomi-
nant activator of transcription in endothelial cells (ECs). NF-κB is
sequestered in the cytoplasm through its interactionwith Inhibitor
of κB (IκB) under basal conditions. In response to inﬂammatory
signaling, activated IκB kinase (IKK) complex can phosphory-
late IκB promoting its proteasomal degradation and thus freeing
NF-κB (which contains a nuclear localization signal) to enter the
nucleus and bind to its transcriptional targets, which include pro-
survival genes, and genes encoding pro-inﬂammatory cytokines
and chemokines and leukocyte adhesion molecules, such as vascu-
lar cell adhesion molecule-1 (VCAM-1) and E-selectin (Figure 1).
Because of the potent inﬂammatory gene network that is activated
by NF-κB, this transcriptional pathway is tightly regulated, and a
host of regulatory networks converge on this pathway to inhibit
basalNF-κBactivity and to resolveNF-κB-mediated inﬂammatory
responses (discussed in more detail below).
Despite the presence of multiple checks and balances that
controlNF-κB activation, aging leads to chronic low-grade inﬂam-
mation driven by constitutively elevated levels of nuclear localized,
active NF-κB (Helenius et al., 2001). This may be mediated in
part by the presence of age-related oxidative stress driven by
elevated levels of reactive oxygen species, which can activate NF-
κB signaling in the endothelium and promote chronic vascular
inﬂammation (Csiszar et al., 2008). Furthermore, DNA damage
accumulated during the aging process can activate NF-κB (Salmi-
nen et al., 2012), and circulating levels of the pro-inﬂammatory
cytokine tumor necrosis factor α (TNF-α) also increase with age
(Schulz et al., 2004), and this cytokine can activate NF-κB sig-
naling in ECs. Aging also induces a senescence phenotype in ECs,
which arrests the proliferation of damaged cells. This cellular state,
known as the senescence-associated secretory phenotype (SASP),
is associated with constitutively active NF-κB signaling and the
secretion of pro-inﬂammatory cytokines (Salminen et al., 2012).
Interestingly, an unbiased assessment of the transcription factor
binding motifs that are activated in aging tissue revealed the NF-
κB motif as being over-represented, and short-term inhibition of
NF-κB signaling could reprogram the gene expression network
towards that of young tissue (Adler et al., 2007). Several recent
studies have additionally shown that antagonizingNF-κB signaling
www.frontiersin.org December 2014 | Volume 5 | Article 422 | 1
Cheng et al. Noncoding RNAs regulate vascular inﬂammation
FIGURE 1 | A network of noncoding RNAs negatively regulates NF-κB
signaling. A key mediator of endothelial cell (EC) activation and vascular
inﬂammation is the transcription factor, NF-κB. In non-stimulated cells, NF-κB
subunits (e.g., p65/p50) are sequestered in the cytoplasm through their
interaction with IκB. In response to inﬂammatory signaling, the IKK complex
phosphorylates IκB, which is then ubiquitylated by β-TRC, leading to its
degradation. This results in the release of NF-κB, allowing it to enter the
nucleus and bind to its transcriptional targets, which include leukocyte
adhesion molecules, chemokines, and cytokines. NF-κB-dependent
microRNAs, such as miR-146a and miR-155 impinge on various stages of the
NF-κB signaling pathway, and play critical roles in attenuating activation of this
pathway. The microRNA targets that have been veriﬁed in ECs are shown as
solid lines, and targets validated in other cell types are indicated with dashed
lines. Flow dynamics play a crucial role in regulating EC activation. Laminar
ﬂow initiates an anti-inﬂammatory gene expression program that includes
up-regulation of transcription factors such as KLF2 and KLF4 that not only
promote the expression of anti-inﬂammatory genes, but also compete with
NF-κB for access to the transcriptional co-activator, p300. Laminar ﬂow
promotes the expression of miR-10a, which negatively regulates NF-κB
activity in ECs by directly targetingTAK1 and β-TRC. In contrast, oscillatory
ﬂow induces − while laminar ﬂow suppresses − the expression of miR-92a,
which targets KLF2 and KLF4, leading to increased inﬂammation. MicroRNAs
can be found at high levels within microvesicles (MVs) in the circulation. The
effects of MVs on EC inﬂammatory pathways are not known, but may include
regulation of signaling pathways or transfer of microRNAs to ECs. Long
noncoding RNAs (lncRNA) have recently been shown to regulate NF-κB
signaling in other cells types, but their effects on EC inﬂammatory pathways
are not yet known.
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can delay aging (Osorio et al., 2012; Tilstra et al., 2012), demon-
strating the key role that this signaling pathway plays in the aging
process of various tissues.
ATHEROSCLEROSIS IS AN INFLAMMATORY DISEASE OF
BLOOD VESSELS
Inﬂammation plays a prominent role in the pathogenesis of
atherosclerosis, a disease characterized by the narrowing of blood
vessels due to the growth of an atherosclerotic plaque (Hans-
son, 2005; Weber and Noels, 2011). In advanced stages of the
disease, plaque rupture with associated thrombosis and vessel
occlusion can result in myocardial infarction and stroke, which
signiﬁcantly contribute to morbidity and mortality in indus-
trialized countries. During the early stages of atherogenesis,
sub-endothelial accumulation of low density lipoprotein (LDL)
and EC dysfunction lead to recruitment of circulating monocytes
(particularly pro-inﬂammatory Ly6Chi monocytes; Swirski et al.,
2007), which differentiate into macrophages and foam cells within
the blood vessel wall (Pober and Sessa, 2007). In response to pro-
inﬂammatory cytokines secreted by these recruited inﬂammatory
cells, ECs become further activated and express high levels of
leukocyte adhesion molecules on their cell-surface, which facil-
itates further monocyte recruitment (Sprague and Khalil, 2009).
Because of this reiterative inﬂammatory process, atherosclerosis
is a chronic inﬂammatory disease that fails to resolve (Hansson,
2005).
Several EC andmonocyte/macrophage signaling pathways have
been implicated in the pathogenesis of atherosclerosis in mouse
models (Weber and Noels, 2011). These include Toll-like recep-
tor 4 (TLR4; Michelsen et al., 2004; den Dekker et al., 2010), CD40
(Donners et al., 2008), and IL-1 receptor (IL-1R) pathways (Devlin
et al., 2002; Kirii et al., 2003), among others. These signaling
pathways share common adaptor proteins [e.g., TNF receptor-
associated factor 6 (TRAF6) and IL-1 receptor-associated kinase
1 (IRAK1); Cao et al., 1996; Lomaga et al., 1999; Hull et al., 2002;
Donners et al., 2008], and signaling through these adaptors results
in the induction of transcription factors of the NF-κB (Figure 1),
activator protein-1 (AP-1) and early growth response (EGR)
families. Upon activation in ECs, these transcription factors coop-
eratively drive the transcription of inducible adhesion molecules
[e.g., VCAM-1, inducible cell adhesion molecule-1 (ICAM-1),
E-selectin (SELE)], cytokines [e.g., TNF-α, Interleukin-1β (IL-
1β)] and chemokines [e.g., monocyte chemoattractant protein-1
(MCP-1)] (Ahmad et al., 1998; Wieland et al., 2005). Impor-
tantly, antagonizingNF-κB (Gareus et al., 2008),AP-1 (Wang et al.,
2011a), or EGR (Harja et al., 2004; Albrecht et al., 2010) pathways
inhibits atherogenesis. It is important to note that while inhibi-
tion of NF-κB activity in the endothelium reduces EC activation
and atherogenesis (Gareus et al., 2008), antagonizing NF-κB in
macrophages worsens atherosclerosis (Kanters et al., 2003), under-
scoring the diversity of NF-κB function in distinct tissues that are
involved in atherogenesis.
NEGATIVE FEEDBACK LOOPS ACT TO RESTRAIN THE
INTENSITY AND DURATION OF NF-κB ACTIVITY
Inﬂammation proceeds through a series of well-orchestrated steps,
ending in resolution (Liew et al., 2005; Serhan et al., 2007). A defect
in resolution appears to contribute to atherogenesis since chronic
vascular inﬂammation is a hallmarkof this disease (Hansson,2005;
Weber and Noels, 2011). Importantly, inﬂammatory signals also
induce the expressionof proteins (Serhan et al.,2007),microRNAs,
and lncRNAs (discussed in detail below) thatmediate resolution at
a later stage of inﬂammation: thereby forming negative feedback
loops. In the context of vascular inﬂammation, transcription of
adhesion molecule genes in ECs must be limited to prevent con-
tinual recruitment of leukocytes (Winsauer and de Martin, 2007).
A classic example of a negative feedback loop is the transcriptional
induction of IκB by NF-κB. IκB facilitates the transport of NF-κB
out of the nucleus to attenuate NF-κB-dependent transcription
(Arenzana-Seisdedos et al., 1995; Figure 1). Several other negative
regulatory loops have also been well characterized. For example,
IRAK-M is induced by inﬂammatory stimuli and is a kinase-
deﬁcient homolog of IRAK1 that inhibits signaling through IRAK1
(Wesche et al., 1999; Kobayashi et al., 2002), and MyD88s, an alter-
natively splicedproduct of MyD88, is also induced and antagonizes
MyD88 to inhibit signaling (Janssens et al., 2002, 2003). Addi-
tionally, A20 (also known as TNFAIP3) is induced by NF-κB and
negatively regulates inﬂammatory signaling by removing activat-
ing (i.e., Lys63) ubiquitinmarks on adaptormolecules such as RIP1
and TRAF6 (Boone et al., 2004;Wertz et al., 2004). Deletion of A20
impairs the resolution of inﬂammation (Boone et al., 2004; Turer
et al., 2008) and enhances atherogenesis (Wolfrum et al., 2007).
IRAK1 protein is also degraded by the proteasome following sig-
naling, which serves to attenuate signal transduction (Yamin and
Miller, 1997).
NONCODING RNAs IN GENE REGULATION
In addition to the identiﬁcation of proteins that serve as nega-
tive feedback regulators of NF-κB, noncoding RNAs, including
microRNAs (discussed below) and long noncoding RNAs (lncR-
NAs; discussed later), have been shown to regulate inﬂammatory
signaling. MicroRNAs are short RNAs (∼21–23 nts) that medi-
ate post-transcriptional gene regulation (Bartel, 2009). They are
transcribed by RNA Polymerase II (Lee et al., 2004), and follow-
ing export/processing into the mature microRNA (Grishok et al.,
2001; Lee et al., 2003; Lund et al., 2004), one strand of the double-
stranded microRNA (the guide strand) is incorporated into the
RNA-induced silencing complex (RISC), which binds to target
messenger RNAs (mRNAs) through partial base-pair complemen-
tarity (Gregory et al., 2005). In general, microRNAs bind to the
3′ untranslated regions (UTRs) of target mRNAs and negatively
regulate mRNA stability and translation (Baek et al., 2008). Exper-
imental validation has demonstrated that a single microRNA can
directly repress the expression of 100s of mRNAs (Baek et al.,
2008). However, only a few microRNA targets may be critical
in dictating the cellular function of a microRNA (Valastyan et al.,
2009). Importantly, mice deﬁcient in just a single microRNA have
profound functional deﬁcits in speciﬁc cellular pathways (Thai
et al., 2007; van Rooij et al., 2007; Wang et al., 2008; Boldin et al.,
2011), suggesting that microRNAs potently regulate key cellular
activities.
The central role of NF-κB in driving inﬂammation necessitates
tight control of this pathway. A growing number of microRNAs
have been implicated in the regulation of NF-κB signaling (Boldin
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and Baltimore, 2012; Gantier et al., 2012; Song et al., 2013). For
the purposes of this review, we will focus on microRNAs that
inﬂuence this pathway in ECs. For example, miR-146a is induced
in ECs by inﬂammatory stimuli and acts to terminate signaling by
targeting upstream components of the NF-κB signaling pathway
(Cheng et al., 2013). Other microRNAs, such as miR-10a (Fang
et al., 2010) and miR-92a (Wu et al., 2011; Fang and Davies, 2012;
Loyer et al., 2014), are regulated by laminar ﬂow, a potent inhibitor
of EC inﬂammatory pathways. In addition, miR-181b is down-
regulated in vascular inﬂammatory diseases such as sepsis and
coronary artery disease (CAD) and functions as an antagonist of
the nuclear import of NF-κB subunits in ECs (Sun et al., 2012,
2014). Although it is not the focus of this review, microRNAs have
also been identiﬁed that directly target key leukocyte adhesion
molecules in activated ECs [e.g., miR-126 targets VCAM1 (Harris
et al., 2008), miR-31 targets SELE and miR-17-3p targets ICAM1
(Suarez et al., 2010)].
MicroRNA-146a (miR-146a) PARTICIPATES IN NEGATIVE
FEEDBACK REGULATION OF NF-κB ACTIVITY AND
CONTRIBUTES TO THE CONTROL OF VASCULAR
INFLAMMATION
SeveralmicroRNAs are induced in response to inﬂammatory stim-
uli in humanmonocytes (Taganov et al., 2006; Bazzoni et al., 2009)
and ECs (Suarez et al., 2010; Cheng et al., 2013). Interestingly, the
NF-κB-dependent induction of miR-146a plays a critical role in
attenuating NF-κB signaling. This is accomplished through the
targeting of TRAF6 and IRAK1, two adaptor proteins that act
upstream of the NF-κB pathway (Taganov et al., 2006; Cheng
et al., 2013; Figure 1). Interestingly, we found that while the
transcription of miR-146a occurs very early during the inﬂam-
matory response in ECs, mature miR-146a does not accumulate
until late in the response, and miR-146a accumulation coincides
with the resolution of the inﬂammatory response (Cheng et al.,
2013). Cultured human ECs treated with miR-146 inhibitors,
as well as miR-146a−/− mice, have an enhanced magnitude
and duration of the EC inﬂammatory response; thus indicat-
ing the functional importance of this microRNA in repressing
vascular inﬂammation (Cheng et al., 2013). In contrast, over-
expression of miR-146a in human ECs suppresses their activation
and inhibits monocyte adhesion (Cheng et al., 2013). In addi-
tion to the targeting of IRAK1/TRAF6, we also identiﬁed the
RNA binding protein, HuR, as a novel miR-146a target, and
found that HuR promotes EC activation through the repression of
an anti-inﬂammatory Kruppel-like Factor 2 (KLF2)/eNOS path-
way (Cheng et al., 2013). More recently, the caspase recruitment
domain family 10 (CARD10), an adaptor protein for GPCR-
mediated NF-κB activity, was identiﬁed as a target of miR-146a
in cultured human ECs (Cowan et al., 2014; Rau et al., 2014).
MiR-146a/b were also previously found to be highly elevated in
senescent human ﬁbroblasts (Bhaumik et al., 2009) and ECs (Vasa-
Nicotera et al., 2011; Olivieri et al., 2013), and ectopic expression
of miR-146a suppressed the SASP phenotype of senescent cells
(Bhaumik et al., 2009).
In addition to the anti-inﬂammatory role of miR-146a in
ECs, this microRNA also plays several important roles in repress-
ing inﬂammatory signaling in immune cells. In monocytes for
example, miR-146a participates in endotoxin tolerance elicited by
lipopolysaccharide (LPS), a bacterial cell wall component. Follow-
ing initial exposure to a low dose of LPS, miR-146a expression
is induced and maintained, allowing for suppression of a sub-
sequent inﬂammatory response to a high dose of LPS (Biswas
and Lopez-Collazo, 2009). Antagonism of miR-146a induction in
human cultured monocytes and in mouse models prevents endo-
toxin tolerance from occurring (Nahid et al., 2009; Banerjee et al.,
2013) and miR-146a−/− mice are hypersensitive to LPS, and pro-
duce extremely high levels of pro-inﬂammatory cytokines that
cause lethal septic shock (Boldin et al., 2011). The expression of
miR-146a is also down-regulated in macrophages exposed to oxi-
dized LDL. Over-expression of miR-146a inhibits LDL cholesterol
uptake by macrophages and the secretion of pro-inﬂammatory
cytokines through targeting of TLR4 (Yang et al., 2011). Further-
more, miR-146a−/− mice produce an expanded population of
pro-inﬂammatory Ly6Chi monocytes in response to inﬂamma-
tory stimulation (Etzrodt et al., 2012), suggesting that the innate
inﬂammatory responsemay be exaggerated andprolonged in these
mice. These mice also have protracted T-cell responses (Yang et al.,
2012), defective regulatory T-cell functions (Lu et al., 2010), and
develop an autoimmune-likemyeloproliferative disease later in life
(Zhao et al., 2011), suggesting that miR-146a-mediated feedback
loops are necessary to prevent prolonged activation of the immune
system.
The role of miR-146a in atherosclerosis remains to be tested.
The collective data above support an anti-inﬂammatory and anti-
atherosclerotic role for miR-146a in ECs and leukocytes. Interest-
ingly, circulating levels of miR-146a increase during atherogenesis
in mice (Sun et al., 2014), and elevated expression of miR-146a
is observed in atherosclerotic plaques in mice (Nazari-Jahantigh
et al., 2012) and in humans (Raitoharju et al., 2011). This increase
in miR-146a expression may be due to the activation of inﬂamma-
tory pathways during the course of disease progression. Deletion
of miR-146a or delivery of miR-146a mimics will be informative
to deﬁne the role of this microRNA in atherogenesis.
MiR-10a and miR-92a CONTRIBUTE TO THE REGULATION OF
NF-κB IN RESPONSE TO BLOOD FLOW
Flowdynamics play a crucial role in regulatingbloodvessel biology,
and regional differences in these dynamics affect inﬂammation and
the progression of atherosclerosis. Areas of the vasculature that are
exposed to uniform laminar ﬂow are protected against inﬂam-
mation and the development of atherosclerosis, while regions
of disturbed ﬂow, which are typically found at branch points,
bifurcations, and the lesser (inner) curvature of arched vessels,
are prone to inﬂammatory activation and plaque formation (Dai
et al., 2004; VanderLaan et al., 2004). Laminar ﬂow initiates a
gene expression program that includes up-regulation of athero-
protective transcription factors such as KLF2 (SenBanerjee et al.,
2004), and inhibition of pro-inﬂammatory transcription factors
such as NF-κB (Dai et al., 2004; Won et al., 2007). Further to
transcriptional programs, blood ﬂow also modulates the expres-
sion of several microRNAs (Qin et al., 2010; Wang et al., 2010b;
Weber et al., 2010b). To identify microRNAs that might con-
tribute to the regulation of vascular inﬂammation, Fang et al.
(2010) performed microRNA arrays on atherosusceptible versus
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atheroprotective regions of the vasculature in swine models, and
found thatmiR-10a is an EC-enrichedmicroRNA that is decreased
in regions that are prone to the development of atherosclerosis,
such as the lesser curvature of the aortic arch. The differen-
tial ﬂow-mediated regulation of miR-10a in the vasculature was
conﬁrmed in mouse models (Fang et al., 2010). These results sug-
gested that laminar ﬂow promotes the expression of miR-10a;
however, it should be noted that miR-10a does not appear to be
regulated by KLF2 (Hergenreider et al., 2012). The aortic arch
experiences disturbed ﬂow dynamics and elevated NF-κB activ-
ity, which suggests that NF-κB may negatively regulate miR-10a
expression. In support of this, Xue et al. (2011) showed that
miR-10a is downregulated by TLR-mediated NF-κB activity in
intestinal dendritic cells. Elucidating the mechanisms responsible
for miR-10a ﬂow-dependent regulation in vivo will require fur-
ther investigation. Functional characterization of this microRNA
revealed that miR-10a negatively regulates NF-κB activity in cul-
tured human ECs by directly targeting MAP3K7 (also known
as TAK1) and β-TRC (Fang et al., 2010; Figure 1). TAK1 is
essential for NF-κB signaling (Sato et al., 2005) as it is a kinase
that activates IKKβ, which is responsible for IκBα phosphory-
lation, while β-TRC mediates ubiquitination of phosphorylated
IκBα, facilitating ubiquitination-mediated protein degradation
(Yaron et al., 1998). The role of miR-10a in atherosclerosis has
not been tested, but the results of Fang et al. (2010) suggest
that miR-10a may suppress atherogenesis; linking ﬂow dynam-
ics with NF-κB signaling. The recent generation of miR-10a
knock-out mice (Stadthagen et al., 2013) will be useful to test this
hypothesis.
A distinct set of microRNAs is induced by disturbed or oscil-
latory ﬂow in cultured human cells. For example, miR-663 is
upregulated by oscillatory ﬂow and drives a pro-inﬂammatory
expression proﬁle and enhances monocyte adhesion to the
endothelium (Ni et al., 2011). Oscillatory ﬂow also induces the
expression of miR-92a in human cells, while atheroprotective
laminar ﬂow down-regulates its expression (Wu et al., 2011).
Interestingly, KLF2 and KLF4 have been shown to be miR-92a
target genes (Wu et al., 2011; Fang and Davies, 2012). These
two transcription factors inhibit NF-κB dependent inﬂamma-
tory genes (SenBanerjee et al., 2004; Hamik et al., 2007) in part
by competing with NF-κB for access to the transcriptional co-
activators p300/CBP (SenBanerjee et al., 2004; Zhou et al., 2012)
(Figure 1). In mice, genetic deﬁciency of either KLF2 or KLF4
in ApoE−/− mice (which develop atherosclerotic lesions when
placed on high fat diet) enhances atherosclerosis, indicating an
atheroprotective role for KLF2 and KLF4 (Atkins et al., 2008;
Zhou et al., 2012). Furthermore, a role for miR-92a-dependent
regulation of KLF2/KLF4 in the pathogenesis of atherosclero-
sis was recently demonstrated. Loyer et al. (2014) found that
endothelial miR-92a expression is induced by a combination
of low shear stress and oxidized LDL, two key factors that
drive EC activation, and they observed that miR-92a levels are
enhanced during atherogenesis in mouse models. Using miR-
92a inhibitors, they observed an increase in KLF2 and KLF4
levels as well as a decrease in total and phosphorylated p65 in
the aortas of atherosclerotic mice, which was accompanied by
diminished atherosclerotic plaque formation (Loyer et al., 2014).
Thus, miR-92a appears to enhance NF-κB signaling at two lev-
els: by repressing KLF2/KLF4, antagonists of NF-κB-dependent
transcription, and by promoting the activation of p65. The mech-
anisms responsible for this latter effect on p65 are not known.
Collectively, these studies underscore the pro-inﬂammatory and
pro-atherogenic function of miR-92a in the endothelium, and link
this microRNA with regulation of ﬂow-dependent transcriptional
programs.
MiR-181b IS DOWN-REGULATED IN VASCULAR
INFLAMMATORY DISEASES AND CONTROLS THE IMPORT OF
NF-κB INTO THE NUCLEUS
To identify microRNAs that might be involved in the inﬂamma-
tory response, Sun et al. (2012) proﬁled microRNA expression in
human ECs exposed to the pro-inﬂammatory cytokine, TNF-α.
They found that miR-181b was rapidly down-regulated by this
stimulus. The miR-181 family consists of four members (miR-
181a, b, c, and d) in human and mouse. The predominant
isoform in ECs is miR-181b, which is expressed at greater than
10-fold higher levels than miR-181a, while the other two iso-
forms are nearly undetectable (Sun et al., 2012). Importantly,
circulating levels of miR-181b are decreased in patients with sep-
sis, a systemic inﬂammatory response that is associated with
EC activation, vascular permeability, and severe organ dam-
age (Sun et al., 2012). This microRNA is also down-regulated
in the circulation and in the intima of atherosclerotic lesions
in mouse models of atherosclerosis, and circulating levels are
lower in patients with CAD (Sun et al., 2014). This suggests
that down-regulation of miR-181b occurs in diverse vascular
inﬂammatory conditions. The over-expression of miR-181b in
cultured human ECs or systemic delivery of miR-181b mim-
ics in mice represses NF-κB dependent vascular inﬂammatory
gene expression. Treatment with miR-181b mimics also decreases
leukocyte recruitment and damage to the lung, and increases
survivability in a mouse model of sepsis (Sun et al., 2012). Sys-
temic mimic injections resulted in miR-181b accumulation in
the intimal region (i.e., ECs) of the aorta and in circulating
leukocytes, with limited accumulation in the medial layer of
the vessel wall. With success in systemic delivery of miR-181b
mimic into mice in an acute inﬂammatory condition (i.e., sep-
sis), their subsequent study demonstrated that multiple injections
of miR-181b mimic can reduce vascular inﬂammation and reduce
lipid-rich plaque accumulation inmousemodels of atherosclerosis
(Sun et al., 2014).
By analyzing the targets of miR-181b, Sun et al. (2012) found
that this microRNA impinges on the NF-κB pathway by tar-
geting the nuclear protein transporter IPOA3 (Importin-3α) in
human and mouse ECs (Figure 1). The IPOA family has been
shown to mediate nuclear import of NF-κB subunits during
the inﬂammatory response (Fagerlund et al., 2005). Interestingly,
the miR-181b-mediated repression of NF-κB activity was only
observed in the endothelium and not in leukocytes, despite efﬁ-
cient delivery of miR-181b to leukocytes (Sun et al., 2014). While
miR-181b represses IPOA3 expression in leukocytes, the main iso-
form used for NF-κB nuclear transport in leukocytes is IPOA5
(which is not targeted by miR-181b): explaining the insensitivity
of leukocytes to miR-181b manipulation. This is an important
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ﬁnding considering that inhibition of NF-κB in ECs and leuko-
cytes can have opposite effects on atherogenesis (Kanters et al.,
2003; Gareus et al., 2008). Collectively, these studies highlight the
importance, and potential therapeutic relevance, of miR-181b in
vascular inﬂammatory diseases.
MiR-155 HAS PLEIOTROPIC ROLES IN CONTROLLING
INFLAMMATION
Since microRNAs can target and repress several genes, they can
have complex effects on signaling pathways. MiR-155 has been
intensely studied for its role in controlling inﬂammation, but in
contrast to miR-146a, miR-10a, miR-92a, and miR-181b, which
appear to have predominantly pro- or anti-inﬂammatory roles,
studies on miR-155 have often revealed conﬂicting roles for this
microRNA. Many of these differences seem to be attributable
to the cell type being studied. For example, miR-155−/− mice
are severely immunocompromised (Rodriguez et al., 2007), and
this appears to be dependent on miR-155 function in B-cells
(Vigorito et al., 2007). These mice are also resistant to auto-
immunity through T-cell mediated effects of miR-155 (O’Connell
et al., 2010). A role for miR-155 in leukocytes during athero-
genesis has also been demonstrated. The levels of miR-155
dramatically increase in atherosclerotic plaques and within plaque
macrophages in mice (Nazari-Jahantigh et al., 2012; Tian et al.,
2014). By utilizing bone marrow transplant approaches, one
report has found that miR-155 promotes the development of
atherosclerotic plaques in the ApoE−/− model by driving an
NF-κB-dependent pro-inﬂammatory response (Nazari-Jahantigh
et al., 2012), whereas another group has found that miR-155
inhibits atherosclerosis in the Ldlr−/− model by antagonizing
the levels of circulating neutrophils and pro-inﬂammatory Ly6Chi
monocytes (Donners et al., 2012). In addition, injection of miR-
155 inhibitors has been shown to reduce plaque formation in
ApoE−/− mice, and this is accompanied by reduced ox-LDL
uptake and less reactive oxygen species production (Tian et al.,
2014). Additional investigations will be required to resolve the
differences in these studies, which used different atheroscle-
rotic mouse models and assessed different time-points of disease
progression.
Several studies have assessed miR-155 function in vascular ECs
and have found a largely anti-inﬂammatory effect. However, it is
important to note that only in vitro experiments have been per-
formed thus far. For example, miR-155 can target angiotensin II
type I receptor (AGTR1) and ETS1 in human ECs. Angiotensin II
(Ang II) is a potent inducer of inﬂammation, and ETS1 has been
shown to drive the expression of VCAM1 and MCP1 in response
to Ang II stimulation. Thus, over-expression of miR-155 inhibits
the pro-inﬂammatory effects of Ang II (Zhu et al., 2011). MiR-
155 is also induced by the pro-inﬂammatory cytokine, TNF-α,
and can act as a negative feedback regulator by directly target-
ing p65 and inhibiting human EC activation (Wu et al., 2014b).
A recent report elegantly demonstrated that miR-155 expression
is repressed by Notch signaling in mouse bone marrow stromal
ECs (Wang et al., 2014). Deletion of Notch in these cells enhances
miR-155 expression and miR-155 can target the NF-κB inhibitor,
κB-Ras1, enhancing NF-κB activity in stromal ECs and driving
pro-inﬂammatory cytokine production and myeloproliferation.
MiR-155 has also been shown to antagonize NF-κB signaling
in other cell types. For example, miR-155 can target MyD88 in
human macrophages (Huang et al., 2010), and TAB2 in human
dendritic cells (Ceppi et al., 2009). MiR-155 also negatively reg-
ulates NF-κB signaling in human epithelial cells during H. pylori
infection (Xiao et al., 2009). Taken together, the role of miR-155
in controlling vascular inﬂammation appears to be highly com-
plex and cell-speciﬁc, and further investigation is required to fully
understand the role of this microRNA in vascular pathology.
LncRNAs ARE AN INTEGRAL PART OF THE NF-κB SIGNALING
NETWORK, BUT THEY HAVE AN UNEXPLORED ROLE IN
VASCULAR INFLAMMATION
Over the past few years, lncRNA have gained increasing recogni-
tion as regulatory molecules. By deﬁnition, lncRNAs are classiﬁed
as RNA transcripts greater than 200 nucleotides in length that
do not code for a functional protein (Sabin et al., 2013). Sim-
ilarly to mRNAs, lncRNAs are RNA polymerase II transcribed,
can be polyadenylated at their 3′ end, and are often spliced.
However, lncRNAs differ from mRNAs in their low conservation
across species, low expression levels, and in many cases, nuclear
accumulation (Guil and Esteller, 2012). LncRNAs are located in
various genomic regions; for example, they can be expressed as
intergenic genes, they can be found within introns of existing
protein-coding genes, they can be antisense to protein-coding
genes, or they can be transcribed from enhancer regions (Schon-
rock et al., 2012). Although lncRNA functions are highly diverse
and are continuing to be uncovered, the most frequently reported
function is their involvement in chromatin remodeling. In fact,
Guttman et al. (2011) showed that 30% of lncRNAs in mouse
embryonic stem cells interact with at least one chromatin remod-
eling complex. Of these, the two most commonly described are
polycomb group (PcG) and trithorax group (TxG) complexes,
which deposit repressive H3K27me3 or activating H3K4me3 his-
tone marks, respectively. In addition, other lncRNA functions
include, but are not limited to: recruitment of transcription
factors to chromatin targets, acting as decoys for cellular pro-
teins, affecting mRNA stability, facilitating chromatin looping,
interacting with microRNAs to modulate their function or pro-
cessing, and acting as a scaffold for protein complex formation
(Rinn and Chang, 2012; Cech and Steitz, 2014; Yang et al., 2014;
Yoon et al., 2014).
While the involvement of lncRNAs in EC biology is just begin-
ning to be explored (Bell et al., 2014; Ge et al., 2014; Michalik et al.,
2014), studies in other cell types have uncovered roles for lncR-
NAs in the control of NF-κB signaling and inﬂammation. One
of the ﬁrst studies to demonstrate the involvement of lncRNAs in
the inﬂammatory response was the demonstration that a lncRNA
located ∼50 kb downstream of mouse Cox2 (named lncRNA-
Cox2) is induced together with Cox2 in mouse bone marrow-
derived macrophages upon exposure to pro-inﬂammatory stimuli
such as LPS (Carpenter et al., 2013). Knock-down of lncRNA-Cox2
and subsequent RNA-seq experiments revealed that lncRNA-Cox2
is capable of affecting the expression of over a thousand genes,
but does not inﬂuence the expression of Cox2 itself (Carpen-
ter et al., 2013). There were 787 up-regulated genes and 713
down-regulated genes with gene ontology enrichment analysis
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revealing a signiﬁcant over-representation of immune response
genes. Although no explanation for how lncRNA-Cox2 can
induce gene expression was provided, the group did show that
lncRNA-Cox2 can interact with heterogeneous nuclear ribonu-
cleoproteins (hnRNP) A/B and A2/B1 to down-regulate target
genes (Carpenter et al., 2013). HnRNPs are nuclear complexes
that affect mRNA processing and stability (Krecic and Swanson,
1999). Thus, this lncRNA–hnRNP interaction provides a model
for how this lncRNA can act in trans (i.e., on distal loci) to
concurrently affect the expression of a large number of genes (Car-
penter et al., 2013). While this lncRNA has not been shown to
directly inﬂuence NF-κB signaling, this example illustrates how
lncRNAs are integrated into the inﬂammatory gene regulatory
network.
In the human genome, a distinct lncRNA is located in proxim-
ity to the COX2 gene. Characterized by Krawczyk and Emerson
(2014), this lncRNA was named P50-associated COX-2 extra-
genic RNA (PACER), is located 1 kb upstream of COX2, and
is transcribed in the antisense direction. Similar to lncRNA-
Cox2, PACER expression is induced following exposure of human
macrophages/monocytes to pro-inﬂammatory stimuli such as
LPS. Under basal conditions PACER expression is repressed, but
LPS stimulation leads to recruitment of CTCF/cohesin and estab-
lishment of an open chromatin environment, allowing for both
PACER and COX2 expression. PACER transcripts are retained
in the nucleus, of which one third are associated with chro-
matin. Unlike lncRNA-Cox2, PACER knock-down affects COX2
expression in cis (i.e., within the same locus). The mechanism
involves the physical interaction of PACER transcripts with the
p50 NF-κB subunit. Thus, PACER acts to impede p50 homod-
imers frombinding to theCOX2 promoter. Since p50 homodimers
are repressive, PACER facilitates the binding of activating p65/p50
heterodimers rather than p50/p50 homodimers to the COX2 pro-
moter, resulting in p300 recruitment, deposition of active histone
acetylation marks throughout the locus, and robust COX2 tran-
scription. Therefore, PACER is induced by inﬂammatory stimuli
and acts in cis to maintain NF-κB-dependent transcription at
the COX2 locus. Whether PACER-p50 interactions affect the
expression of other NF-κB-regulated genes in trans remains to be
investigated.
PACER is not the only lncRNA reported to physically interact
with NF-κB subunits. A study by Rapicavoli et al. (2013) dis-
covered another lncRNA in mice, Lethe, which interacts with
the p65 NF-κB subunit. Lethe was identiﬁed as the lncRNA
with the highest fold change upon TNF-α or IL-1β treatment of
mouse embryonic ﬁbroblasts. Further characterization revealed
that Lethe is enriched in the nucleus and is associated with
chromatin. Within the nucleus, Lethe acts as a negative reg-
ulator of NF-κB signaling by binding and sequestering the
p65 subunit. Therefore, Lethe participates in a negative feed-
back loop, as it is an NF-κB inducible transcript, which then
acts to turn off expression of NF-κB-regulated genes. Whether
Lethe has a human ortholog or has a function in ECs is
unknown.
Recently, noncoding RNAs produced from gene enhancers
[e.g., enhancer RNAs (eRNAs) and regions of bidirectional tran-
scription (RBT)] have been shown to play a critical role in gene
induction (Lam et al., 2014). The function of eRNAs is still poorly
understood, but they appear to promote transcription by mediat-
ing gene looping between enhancers and promoters through their
recruitment of cohesin complex components (Li et al., 2013b), or
by inﬂuencing chromatin accessibility of genepromoters (Mousavi
et al., 2013). A large number (>100) of eRNAs and RBTs are
induced in human monocytes stimulated with LPS (IIott et al.,
2014). Within the IL-1β locus, one eRNA (IL-1β-eRNA) located
downstream, and two RBTs [IL-1β-RBT-46(+) and IL-1β-RBT-
46(−)] located upstream of IL-1β are induced by LPS stimulation.
These transcripts are NF-κB-dependent and are enriched in the
nucleus, and their induction kinetics mirror that of IL-1β mRNA
(IIott et al., 2014). Typical of eRNAs/RBTs, IL-1β-eRNA and IL-
1β-RBT-46 were shown to act in cis, as their silencing led to
decreased IL-1β mRNA and IL-1β protein levels. However, these
eRNAs/RBTs may have additional direct and indirect target genes
since the expression of CXCL8 (which is located on a differ-
ent chromosome), was also affected by their knock-down. Thus,
eRNAs are also integrated into the NF-κB signaling network, but
their mechanisms of action are poorly understood.
Despite our increasing appreciation of the impact of lncR-
NAs in the context of the inﬂammatory response, many questions
remain unanswered. In particular, the effect of lncRNAs on NF-κB
signaling is only beginning to be studied, with the majority of
studies thus far performed in monocytes/macrophages ex vivo.
The role of lncRNAs in EC inﬂammatory pathways is currently
unknown. Sincemany lncRNAs are expressed in a cell-type speciﬁc
fashion, there is likely to be a wealth of novel lncRNAs to be uncov-
ered that may participate in EC inﬂammation and atherosclerosis.
Interestingly, recent studies are beginning to implicate lncRNAs
in controlling atherogenesis. For example, lncRNA-p21 is down-
regulated in mouse models of atherosclerosis (Wu et al., 2014a).
Further characterization revealed that this lncRNA represses the
proliferation of smooth muscle cells and its inhibition in a mouse
carotid artery injury model enhances neointimal formation (Wu
et al., 2014a). In addition, the lncRNA ANRIL, which is located
in the 9p21.3 CAD susceptibility locus in humans (McPherson
et al., 2007), appears to regulate smooth muscle cell proliferation
(Jarinova et al., 2009; Motterle et al., 2012; Holdt et al., 2013), but
the mechanism of action is still incompletely understood (Chen
et al., 2014). These ﬁndings demonstrate that lncRNAs are likely to
have a major impact on atherosclerotic disease, providing a strong
impetus to further identify the lncRNAs involved in controlling
the vascular inﬂammatory response.
LEVELS OF CIRCULATING microRNAs ARE ALTERED IN
CARDIOVASCULAR DISEASE, BUT THEIR FUNCTIONS ARE
POORLY UNDERSTOOD
Recent studies have reported the presence of microRNAs in con-
ditioned media in vitro (Zhang et al., 2010), as well as in blood,
and other body ﬂuids (e.g., saliva, urine, and milk; Weber et al.,
2010a). MicroRNAs can be secreted from cells within small
membrane-bound vesicles called microvesicles (MVs), or they can
be associated with RNA-binding proteins such as Argonaute 2
(Arroyo et al., 2011) or Nucleophosmin (Wang et al., 2010a). The
packaging of microRNAs into MVs or protein complexes pro-
tects them from degradation and confers the surprisingly high
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stability of microRNAs in blood and other body ﬂuids (Mitchell
et al., 2008). Three types of MVs are released by cells: micropar-
ticles (MPs), exosomes, and apoptotic bodies (ABs; Mittelbrunn
and Sanchez-Madrid, 2012). MPs are a heterogeneous popula-
tion of vesicles (100–1000 nm) produced by plasma membrane
blebbing due to the disruption of membrane phospholipid asym-
metry (Hamon et al., 2000). These vesicles are released from
most cell types in response to stress, such as cell activation or
apoptosis (Combes et al., 1999; Simoncini et al., 2009; Leroyer
et al., 2010). In contrast, exosomes are smaller and more homo-
geneous in size (30–100 nm) and are formed as intraluminal
vesicles inside multivesicular bodies of the endosomal compart-
ment (Heijnen et al., 1999; Simons and Raposo, 2009). They
are released into the extracellular environment by exocytosis in
a constitutive manner and in high quantities. ABs, the largest
vesicles (1–5 μm), are membrane blebs released from apoptotic
cells (Hristov et al., 2004). In addition to microRNAs, MVs also
contain various membrane proteins and lipids, soluble proteins
and genetic information (i.e., mRNA and DNA) derived from
their parental cell. Interestingly, it appears that some microR-
NAs may be selectively loaded or excluded from MVs, since their
abundance differs from their parental cell (Pigati et al., 2010;
Li et al., 2013a).
Several studies have reported the presence of MPs in the
plasma of healthy volunteers, and have found that MP lev-
els increase dramatically under pathological conditions, such as
cardiovascular diseases. For example, the levels of endothelial-
derived MPs are elevated in patients with CAD (Mallat et al.,
2000; Bernal-Mizrachi et al., 2003; Bulut et al., 2009; Nozaki
et al., 2009). Furthermore, high concentrations of leukocyte-
derived plasma MPs are associated with unstable plaque in
high-grade carotid stenosis patients (Sarlon-Bartoli et al., 2013).
Thus, a high level of MPs in the blood is a potential diag-
nostic biomarker for cardiovascular risk. MPs have potent pro-
inﬂammatory properties, as MPs derived from LPS-stimulated
monocytes can activate ECs (Wang et al., 2011b), and con-
versely, MPs produced by ECs can activate monocytes (Jy et al.,
2004). However, whether microRNA transfer is involved in the
pro-inﬂammatory effects of MPs has not yet been studied. Inter-
estingly, microRNA content in the blood can be used as a
biomarker to identify patients at risk for cardiovascular diseases.
Fichtlscherer et al. (2010) have shown that the circulating levels
of vascular microRNAs, including miR-126 and two members
of the miR-17-92 cluster (miR-17 and miR-92a) are decreased
in CAD patients compared to healthy controls, whereas car-
diac muscle microRNAs (miR-133a, miR-208a) are enriched.
Inﬂammation-associated microRNAs are also potential biomark-
ers for vascular diseases, since miR-155 and miR-181b are reduced
in human plasma from patients with CAD (Fichtlscherer et al.,
2010; Sun et al., 2014).
Besides their potential for being utilized as diagnostic biomark-
ers for disease,MVs are capable of modulating numerous (patho-)
physiological processes, including thrombosis, inﬂammation,
angiogenesis, and vascular tone (VanWijk et al., 2003; Leroyer et al.,
2010). They contain bioactive molecules (i.e., lipids and proteins)
that give them an intrinsic biological activity (Simoncini et al.,
2009; Leroyer et al., 2010; Lacroix et al., 2012), and they can also
participate in intercellular communication by transferring func-
tional mRNAs and microRNAs to recipient cells (Zernecke et al.,
2009; Zhang et al., 2010; Hergenreider et al., 2012; Zhou et al.,
2013; Bang et al., 2014; Okoye et al., 2014). For example, Hergen-
reider et al. (2012) showed that miR-143/145 are enriched in MVs
secreted from cultured human ECs exposed to laminar ﬂow or
from ECs over-expressing the shear-responsive transcription fac-
tor KLF2. These endothelial MVs can induce an atheroprotective
phenotype in co-cultured smooth muscle cells in vitro. Moreover,
injection of endothelial-derived miR-143/145-containing MVs
reduces the formation of atherosclerotic lesions in the aortas of
atherosclerotic mice (Hergenreider et al., 2012). In another study,
Zernecke et al. (2009) demonstrated that endothelial derived-ABs
increase the production of an anti-apoptotic survival factor, the
chemokine CXCL12, via the transfer of miR-126 to ECs. Systemic
injection of miR-126-enriched ABs reduces atherosclerotic plaque
size in mouse models of atherosclerosis. This atheroprotective
effect is lost when mice are treated with endothelial ABs isolated
frommiR-126−/− mice (Zernecke et al., 2009), suggesting that this
effect is mediated by the delivery of miR-126 to vascular cells. In
addition to MVs, HDL and LDL particles have also been shown
to contain distinct microRNAs, and the microRNAs contained
in these particles are altered during atherosclerosis (Vickers et al.,
2011). Interestingly, miR-223 can be transferred from HDL par-
ticles to ECs to suppress ICAM-1 expression and EC activation
(Tabet et al., 2014). Taken together, these studies are beginning to
shed light on the role of secreted and/or circulating microRNAs
in the control of atherosclerosis. However, many aspects of the
biology of secreted microRNAs in cardiovascular diseases remain
unknown. For example, it is not clearwhether secretedmicroRNAs
can affect NF-κB signaling and vascular inﬂammation. However,
the fact that circulating miR-181b levels are reduced in septic
patients and in CAD patients (Sun et al., 2012, 2014), and consid-
ering the known role for miR-181b in suppressing NF-κB activity,
this suggests that circulating microRNAs may indeed inﬂuence
vascular inﬂammation. Much remains to be uncovered in this
burgeoning area of research.
RNA-BASED THERAPEUTICS TO TREAT VASCULAR
INFLAMMATION
Considering the important effects that microRNAs have on con-
trolling vascular inﬂammation, interest has focused on developing
therapeutics that target microRNA-regulated gene expression
networks. MicroRNAs are promising targets since they often
regulate a network of genes in a given pathway (Figure 1),
which may limit the development of resistance to treatment,
which is a major drawback of single target therapies (van Rooij
and Kauppinen, 2014). Two approaches can be envisioned:
over-expressing anti-inﬂammatory microRNAs or inhibition of
pro-inﬂammatory microRNAs. The over-expression of microR-
NAs in the vasculature can be achieved by intravascular delivery
of microRNA mimics (Sun et al., 2012, 2014). This is typi-
cally achieved by liposome-mediated delivery modalities, and
the effectiveness of this strategy is illustrated by studies utilizing
miR-181b over-expression in ECs to inhibit vascular inﬂamma-
tion and atherosclerosis in mouse models (Sun et al., 2012, 2014).
Phase I clinical trials are also underway to replace microRNAs
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that are down-regulated in liver cancer (van Rooij and Kaup-
pinen, 2014). However, the potential for non-target cell uptake
is high, and the functional effects of such off-target effects are
not well understood. This is especially relevant considering the
pro- and anti-atherogenic effects of NF-κB in ECs and mono-
cytes/macrophages, respectively (Kanters et al., 2003; Gareus et al.,
2008). Interestingly, systemic delivery of miR-181b inhibits NF-κB
in the endothelium through the targeting of IPOA3, but because
monocytes/macrophages utilize a distinct Importin for NF-κB
activation, no effect on NF-κB signaling is observed in these cells
(Sun et al., 2014). Additional approaches to achieve more nar-
row cell-speciﬁcity of ectopic microRNA expression include the
use of adeno-associated viruses that have natural or engineered
tropism for particular cell types (White et al., 2004; Work et al.,
2006), or the use of cell-speciﬁc promoters to drive microRNA
expression (Lovren et al., 2012). Recent work has also identiﬁed
nanoparticles that deliver siRNAs preferentially to ECs in vivo
(Dahlman et al., 2014). These nanoparticles may also be effec-
tive for the delivery of microRNA mimics speciﬁcally to ECs.
Finally, MVs have been engineered to deliver siRNAs to spe-
ciﬁc cell types (Alvarez-Erviti et al., 2011), suggesting that this
approach may also be feasible for microRNA mimic delivery to
the vasculature.
Therapeutic strategies to inhibit microRNA expression have
been widely used in pre-clinical studies, and are beginning to be
used in clinical settings. Sustained knock-down of microRNA
activity throughout the body can be achieved by intravascu-
lar or subcutaneous injection of anti-sense antagomirs, which
are typically cholesterol-conjugated to improve tissue distribu-
tion (Krutzfeldt et al., 2005). These approaches are appropriate
for microRNAs that are expressed exclusively in a disease con-
dition or are expressed in a cell-restricted fashion, since it is
difﬁcult to achieve tissue-speciﬁc delivery. Such approaches have
been used to inhibit miR-92a expression to promote functional
recovery following ischemia/reperfusion injury in large animal
(i.e., porcine) studies (Hinkel et al., 2013) or to inhibit athero-
genesis in mouse models (Loyer et al., 2014). Recently, the
ﬁrst Phase II clinical trial for a microRNA-based therapeutic
was completed, and has shown promising results. The liver-
speciﬁc microRNA, miR-122, is required for Hepatitis C virus
(HCV) replication (Jopling et al., 2005). Inhibition of miR-122
was previously shown to reduce HCV titer in infected chim-
panzees without toxic effects or the development of resistance
mutations (Lanford et al., 2010). Recent Phase II results using
an anti-miR-122 drug called Miravirsen (Santaris Pharma) have
revealed that ﬁve injections over the course of a month could
reduce HCV viral titer in a dose-dependent fashion, and this
effect was long lasting (>3 months) and did not elicit com-
pensatory mutations in the HCV genome (Janssen et al., 2013).
While some patients displayed a rise in HCV titer at later time-
points following cessation of treatment, these results are very
promising and suggest that similar approaches may be utilized
for cardiovascular diseases. However, it is important to note
that cardiovascular diseases typically develop over long periods
of time, so sustained therapeutic treatment may be difﬁcult to
achieve. Acute vascular inﬂammatory disorders, such as sepsis
and myocardial infarction may therefore be more amenable to
treatment in the short term, while treatment of atherosclero-
sis will likely require signiﬁcant advances in mimic/antagomir
delivery.
CONCLUSION
It is now abundantly clear that noncoding RNAsmodulateNF-κB-
driven responses during vascular inﬂammation. Further research
will likely unearth additional noncoding RNAs, including lncR-
NAs, that provide additional layers of regulation to ﬁne-tune the
inﬂammatory response and contribute to vascular diseases such as
atherosclerosis. Since aging has a large impact on the acquisition
of vascular inﬂammation, it will be interesting to determine the
effect of aging on noncoding RNA-dependent regulation of NF-κB
signaling in the vasculature. The inﬂuence of circulating microR-
NAs on vascular inﬂammation will also be of signiﬁcant interest.
Much of the work linking microRNAs to vascular inﬂammation
has been conducted in mouse models of acute (i.e., sepsis) or
chronic vascular inﬂammation (i.e., atherosclerosis). Mouse mod-
els will continue to be useful in deﬁning the role of microRNAs
in vascular inﬂammation, by either using genetic manipulation or
through the use of microRNAmimics or inhibitors. Mice and large
animal models (i.e., porcine and chimpanzee) will also serve as an
important pre-clinical model for the development of therapeutics
aimed at microRNA-regulated pathways. Mouse models and the
use of humanpatient sampleswill be highly informative for studies
of the biology of circulatingmicroRNAs. Given the limited conser-
vation of lncRNAs, the use of model organisms may be of limited
utility, and studies using cultured human cells will be necessary to
understand their biology. Given the promise of microRNA-based
therapeutics in Hepatitis C (Janssen et al., 2013), it will be exciting
to watch for developments of therapies that harness the ability of
microRNAs to regulate NF-κB signaling in vascular diseases.
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